PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29856819-10	2018	Thus, activatable fluorescence imaging using the Pan-ICG conjugate detected EGFR-positive mediastinal lymph node metastases with high specificity.	Indocyanine Green	53-56	epidermal growth factor receptor	Mus musculus	76-80	
24284098-0	2013	Photodynamic therapeutic effect of indocyanine green entrapped in polymeric nanoparticles and their anti-EGFR-conjugate in skin cancer in CD1 mice.	Indocyanine Green	35-52	epidermal growth factor receptor	Mus musculus	105-109	
24284098-3	2013	The study objective is to investigate the PDT effect of free ICG-PEBBLE and its Anti-EGFR conjugate.	Indocyanine Green	61-64	epidermal growth factor receptor	Mus musculus	85-89	
24284098-5	2013	RESULTS: PDT using ICG-PEBBLE or ICG-PEBBLE-Anti-EGFR decreased skin tumor sizes.	Indocyanine Green	33-36	epidermal growth factor receptor	Mus musculus	49-53	
24284098-7	2013	CONCLUSION: The present study indicated the effectiveness of PDT using ICG-PEBBLE or ICG-PEBBLE-Anti-EGFR as an inhibitor modality for tumor size, apoptosis, angiogenesis and tumor inflammation.	Indocyanine Green	85-88	epidermal growth factor receptor	Mus musculus	101-105	
24284098-8	2013	The conjugating of ICG-PEBBLE to anti-EGFR was found to be more effective in inhibiting VEGF and in increasing caspase-3 compared to free ICG-PEBBLE, but there were no other preferential PDT efficacy.	Indocyanine Green	19-22	epidermal growth factor receptor	Mus musculus	38-42	
26168727-0	2015	In vivo photoacoustic imaging of cancer using indocyanine green-labeled monoclonal antibody targeting the epidermal growth factor receptor.	Indocyanine Green	46-63	epidermal growth factor receptor	Mus musculus	106-138	
26168727-2	2015	The aim of this study was to evaluate the effectiveness of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab; Pan) labeled with indocyanine green derivative (ICG-EG4-Sulfo-OSu), Pan-EG4-ICG, as a PA imaging probe to target cancer-associated EGFR.	Indocyanine Green	159-176	epidermal growth factor receptor	Mus musculus	62-99	
26168727-2	2015	The aim of this study was to evaluate the effectiveness of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab; Pan) labeled with indocyanine green derivative (ICG-EG4-Sulfo-OSu), Pan-EG4-ICG, as a PA imaging probe to target cancer-associated EGFR.	Indocyanine Green	159-176	epidermal growth factor receptor	Mus musculus	101-105	
26168727-2	2015	The aim of this study was to evaluate the effectiveness of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab; Pan) labeled with indocyanine green derivative (ICG-EG4-Sulfo-OSu), Pan-EG4-ICG, as a PA imaging probe to target cancer-associated EGFR.	Indocyanine Green	189-192	epidermal growth factor receptor	Mus musculus	62-99	
26168727-2	2015	The aim of this study was to evaluate the effectiveness of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab; Pan) labeled with indocyanine green derivative (ICG-EG4-Sulfo-OSu), Pan-EG4-ICG, as a PA imaging probe to target cancer-associated EGFR.	Indocyanine Green	189-192	epidermal growth factor receptor	Mus musculus	101-105	
26168727-2	2015	The aim of this study was to evaluate the effectiveness of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab; Pan) labeled with indocyanine green derivative (ICG-EG4-Sulfo-OSu), Pan-EG4-ICG, as a PA imaging probe to target cancer-associated EGFR.	Indocyanine Green	189-192	epidermal growth factor receptor	Mus musculus	272-276	
24284098-8	2013	The conjugating of ICG-PEBBLE to anti-EGFR was found to be more effective in inhibiting VEGF and in increasing caspase-3 compared to free ICG-PEBBLE, but there were no other preferential PDT efficacy.	Indocyanine Green	138-141	epidermal growth factor receptor	Mus musculus	38-42